O. Yvellez

Simplification of Validated Patient-Reported Outcome Instruments in Inflammatory Bowel Disease

D. Rubin, M. Andersen, D. Lei, 2018, Crohn's & Colitis 360.

Ciclosporin therapy after infliximab failure in hospitalized patients with acute severe colitis is effective and safe.

D. Rubin, S. Dalal, J. Pekow, 2019, Journal of Crohn's & colitis.

Cumulative Histologic Inflammation Predicts Colorectal Neoplasia in Ulcerative Colitis: A Validation Study.

D. Rubin, C. Weber, J. Turner, 2020, Inflammatory bowel diseases.

A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab.

A. Gils, B. Subotić, D. Tarabar, 2022, Inflammatory bowel diseases.

P051 IBD PATIENT COMPLIANCE WITH MOBILE AND WEARABLE TECHNOLOGIES AS TOOLS TO ASSESS QUALITY OF LIFE, SLEEP QUALITY AND PAIN

D. Rubin, M. Golan, N. Zmeter, 2018 .

The use of tofacitinib in the treatment of inflammatory bowel disease.

D. Rubin, M. Golan, R. Weisshof, 2018, Immunotherapy.

DOP049 Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant ulcerative colitis patients: A prospective study

D. Rubin, B. Subotić, Z. Milenkovic, 2018 .